project id: TCGA-BLCA; case submitter id: TCGA-G2-A3IB; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.4; rna integrity number: 7.4; age at index: 66; days to birth: -24149; days to death: 220; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Dead; year of birth: 1942; age at diagnosis: 24149; ajcc clinical t: T2a; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage II; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 214.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2008; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1248; days to sample procurement: 0; initial weight: 160.0; portion submitter id: TCGA-G2-A3IB-01A-11; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;